If you need any product or service please register as the Farmavita.Net network member and publish your needs.
License-in is very cost effective way of product development. In the most of the licensing cases you will pay only share of total development cost for the pharmaceutical product.
Published license-out opportunities are alphabetically listed according to pharmaceutical INN name.
Please choose the category below:
Member of Farmavita:net offer Dossier and license for Epoprostenol
CTD with supply agreement and marketing authorization
Epoprostenol 0.5 mg and 1.5 mg (Powder and Solvent for Solution for Infusion)
Epoprostenol is indicated for:
Pulmonary Arterial Hypertension Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ociated with connective tissue diseases) in patients with WHO Functional Cl III-IV symptoms to improve exercise capacity.
Renal Dialysis Epoprostenol is indicated for the use in haemodialysis in emergency situations when use of heparin carries a high risk of causing or exacerbating bleeding or when heparin is otherwise contraindicated.